Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
UMDNJ-Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
UMDNJ-Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
New York University Langone Medical Center
mi
from
New York, NY
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Columbia University Medical Center
mi
from
New York, NY
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
University of Rochester
mi
from
Rochester, NY
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Medical University of South Carolina
mi
from
Charleston, SC
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Baylor College of Medicine
mi
from
Houston, TX
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
The Children's Hospital at Westmead
mi
from
Sydney,
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
The Children's Hospital at Westmead
mi
from
Sydney,
Click here to add this to my saved trials
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated:  11/14/2017
University of California, San Francisco, Medical Center at Parnassus
mi
from
Frisco, CA
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Status: Enrolling
Updated: 11/14/2017
University of California, San Francisco, Medical Center at Parnassus
mi
from
Frisco, CA
Click here to add this to my saved trials
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies
Status: Enrolling
Updated:  11/15/2017
Texas Children's Hospital
mi
from
Houston, TX
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies
Status: Enrolling
Updated: 11/15/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Gluten Free Diet for AML Patients Undergoing Induction Chemotherapy
Status: Enrolling
Updated:  11/15/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Gluten Free Diet for AML Patients Undergoing Induction Chemotherapy
Status: Enrolling
Updated: 11/15/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  11/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 11/15/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  11/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 11/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Santa Monica, CA
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Detroit, MI
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
San Antonio, TX
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Tacoma, WA
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Houston, TX
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Chicago, School of Medicine
mi
from
Chicago, IL
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Chicago, School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Maryland
mi
from
Baltimore, MD
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Michigan
mi
from
Ann Arbor, MI
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
University of Maryland
mi
from
Baltimore, MD
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Karmanos Cancer Center
mi
from
Detroit, MI
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/20/2017
Peter MacCallum Cancer Centre
mi
from
East Melbourne,
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/20/2017
Peter MacCallum Cancer Centre
mi
from
East Melbourne,
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Stanford University Medical Center, Division of Hematology
mi
from
Stanford, CA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Stanford University Medical Center, Division of Hematology
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst.
mi
from
Atlanta, GA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Georgia Regents University MedCollege of GA Cancer Ctr 2
mi
from
Augusta, GA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Georgia Regents University MedCollege of GA Cancer Ctr 2
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc.
mi
from
Skokie, IL
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc.
mi
from
Skokie, IL
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2)
mi
from
Somerset, NJ
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2)
mi
from
Somerset, NJ
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated:  11/27/2017
Duke University Medical Center Dept. of DUMC (4)
mi
from
Durham, NC
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Status: Enrolling
Updated: 11/27/2017
Duke University Medical Center Dept. of DUMC (4)
mi
from
Durham, NC
Click here to add this to my saved trials